Kornimate/medical-research-clean huggingface dataset:
impact of prediabetes on acute coronary syndrome

Conditions: Diabetic Cardiomyopathy

Summary: diabetes mellitus is one of the chronic non-communicable diseases which have emerged as a leading global health problem. according to the international diabetes federation atlas guideline report, currently, there are 352 million adults with impaired glucose tolerance who are at high risk of developing diabetes in the future. in 2017, it was estimated that 425 million people (20-79 years of age) suffered from diabetes mellitus, and the number is expected to rise to 629 million by 2045. moreover, egypt is considered one of the top 10 countries in the world

acute coronary syndrome refers to a constellation of symptoms compatible with acute myocardial ischemia. the syndrome includes systolic time segment elevation myocardial infarction non-systolic time segment elevation myocardial infarction and unstable angina. patients have an over tenfold risk for cardiovascular disease in their lifetime. in the united states, 77% of diabetes-related hospital admissions are for cardiovascular complications. a key feature of diabetes contributing to this is the development of accelerated atherosclerosis. prediabetes is a collective term that encloses individuals with glucose levels lower than cutoff levels for diabetes but too high to be considered normal. fasting blood glucose 6.1 mmol/l- \ 7.8 mmol/l-\<11.1 mmol/l4. prediabetes is associated with a significant increase in cardiovascular morbidity and mortality and necessitates early and adequate intervention to prevent the development of complications, and progression to overt diabetes. higher fasting glucose levels in patients with the acute coronary syndrome were associated with worse clinical outcomes irrespective of the presence of diabetes mellitus. similarly, higher fasting glucose was a marker of adverse outcomes in patients without diabetes presenting with acute systolic time segment elevation myocardial infarction. impaired glucose tolerance is common among non-diabetic patients admitted with the acute coronary syndrome. however, evidence is controversial regarding the prognostic impact of 'prediabetes' on the clinical outcome

Eligibility criteria:
inclusion criteria: * all patients with acute coronary syndrome * diabetic patients and will be subdivided into controlled and uncontrolled pre-diabetic patients. * non-diabetic patient(controlled) exclusion criteria: * patient under 18 years old * pregnancy * chronic kidney disease * familiar hyperlipidemia.
correlation between spinopelvic alignment and uterine dimensions in primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study was conducted to investigate the correlation between spinopelvic alignment and uterine dimensions in primary dysmenorrhea.

primary dysmenorrhea (pd) is a common condition characterized by severe menstrual cramps and lower abdominal pain before or during menstruation, without any underlying pelvic pathology. it is highly prevalent among adolescents and young women, with 16% to 93% of adolescents and 70% to 90% of young women experiencing pd. the severe menstrual discomfort associated with pd often leads to absenteeism from school or work, with approximately one-third to half of individuals missing at least one day per menstrual cycle, and 5% to 14% experiencing more frequent absences. while the exact etiology of pd is not fully understood, researchers have proposed a potential relationship between pd and musculoskeletal factors. one hypothesis suggests that abnormal pelvic and lumbar spine alignment, coupled with abdominal muscle spasms, may affect the positioning of the uterus, increasing the susceptibility to dysmenorrhea. additionally, lumbar spine misalignment could potentially impact uterine blood supply through vasoconstriction, contributing to menstrual pain. spinal misalignment has been proposed as a possible underlying cause of pd, with some studies suggesting that manual therapy techniques may alleviate pd symptoms. furthermore, a lack of coordination between the pelvic floor muscles and surrounding soft tissues has also been implicated as a potential causative factor. however, research investigating the relationship between pd and musculoskeletal factors remains limited, and further exploration of the biomechanical factors influencing the pelvic region is needed. therefore, this study aimed to investigate the correlation between spinopelvic alignment and uterine dimensions in primary dysmenorrhea.

Eligibility criteria:
inclusion criteria: * virginal and non-smokers. * they should have regular menstrual cycles, verified through a three-month calendar record, with cycle durations averaging between 28 to 35 days. * the body mass index (bmi) varied between 18.5 to 25 kg/m2. * additionally, girls in the study group should have moderate to severe pd (walidd score ≥ 5). exclusion criteria: * pelvic or gynecological disorders. * musculoskeletal disorders as low back pain. * spinal deformities as kyphosis and scoliosis. * history of lower limb injuries. * diabetes. * cardiopulmonary diseases. * any physical impairment. * they didn't use analgesics, non-steroidal anti-inflammatory drugs or oral contraceptives.

Keywords: spinal alignment pelvic alignment uterine dimensions primary dysmenorrhea
composition and function of gut microbiota in porto-sinusoidal vascular disease associated with variable common immunodeficiency

Conditions: Common Variable Immunodeficiency; Vascular Diseases

Summary: this aim of this study is the evaluation of the gut microbiota imbalance occurrence and its characterization in patients with common variable immunodeficiency associated to an enteropathy with or without porto-sinusoidal vascular disease.

common variable immunodeficiency (cvid) is the most common symptomatic humoral deficiency in adults and is accompanied by digestive symptoms. it is associated with intestinal dysbiosis and half of the patients exert a clinical digestive disease, called enteropathy. hepatic complications characterized by porto-sinusoidal vascular disease are observed in 10% of the cvid patients. this complication is associated with a high morbi-mortality. in our center experience and in the literature, clinical occurrence of enteropathy and hepatic disease are highly correlated. considering (i) the anatomical link between the intestinal tractus and the portal circulation, (ii) the clinical correlation between enteropathy and the liver disease and (iii) the established relation between gut microbiota and alcoholic cirrhosis, we speculate that patients whom develop portosinusoidal complications exert a peculiar intestinal dysbiosis. this study could contribute to a better understanding of the hepatic disease development, hence allowing us to suggest novel therapies based on gut microbiota modification.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients with a common variable immunodeficiency according to immune deficiencies classification associated with : * enteropathy and porto-sinusoidal vascular disease * enteropathy without porto-sinuoidal vascular disease * subject with health insurance (ame excepted) * verbal agreement to participate at the study exclusion criteria: - laxatives in the month preceding stool sample

Keywords: common variable immunodeficiency porto-sinusoidal vascular disease gut microbiota
single iv administration of tb-402 for prophylaxis of venous thromboembolic events (vte) after total hip replacement surgery

Conditions: Prophylaxis of Venous Thromboembolic Events

Summary: the purpose of this study is to evaluate the safety and efficacy of two doses of tb-402 administered as a single intravenous infusion for the prevention of vte in subjects undergoing total hip replacement surgery.


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged ≥ 18 years. 2. written informed consent. 3. willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures exclusion criteria: 1. pregnancy at the time of screening. 2. indication for anticoagulation other than post-operative thromboprophylaxis. 3. active bleeding or high risk of bleeding. 4. anticipated continued use of neuraxial catheter after surgery. 5. clinical laboratory findings at screening of thrombocytopenia or prolonged aptt or pt. 6. uncontrolled hypertension. 7. impaired liver function (transaminase \>3 x uln) or history of hepatic insufficiency. 8. creatinine clearance \<30 ml/min. 9. antiplatelet agents other than low dose aspirin (\< 200mg). 10. the use of intermittent pneumatic compression. 11. known hypersensitivity to contrast media or rivaroxaban. 12. known drug or alcohol abuse. 13. active malignant disease or current cytostatic treatment. 14. stroke within the previous month. 15. participation in an investigational drug study within the past 30 days or previous participation in this study. 16. any condition that in the opinion of the investigator would put the subject at increased risk from participating in the study or expected inability to comply with the protocol.
mobile application to improve health-related outcomes in patients with advanced lung cancer

Conditions: Lung Cancer

Summary: multi-site randomized trial of the thrive digital health application versus usual care to evaluate the effect of thrive on quality of life (qol), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer.

multi-site randomized controlled trial of the thrive digital health application versus usual care in 250 patients diagnosed with advanced lung cancer within the previous 12 weeks to examine the effect of the intervention on patient-reported qol, physical symptoms, anxiety and depression symptoms, coping, and self-efficacy. participants will be randomized in a 1:1 fashion and stratified by study site and lung cancer type to ensure a balanced representation of these factors between the two study groups. the study team will provide ipads to patients assigned to thrive and provide instructions on how to use the ipad and digital app. the study team will administer patient-reported outcome measures at enrollment and again at six, 12, and 24 weeks post-enrollment to evaluate the short and long-term impact of thrive.

Eligibility criteria:
inclusion criteria: * adults (greater than or equal to 18 years) * diagnosed with advanced non-small cell lung cancer (nsclc) that is not being treated with curative intent or extensive stage small cell lung cancer (sclc) within the past 12 weeks. * eastern cooperative oncology group (ecog) performance status (ps) = 0-2 (i.e., fully active to at least ambulatory and up and about more than 50% of waking hours). * sufficient english proficiency to utilize thrive in english (note: patients can complete outcome measures in spanish if preferred). exclusion criteria: * significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures.

Keywords: quality of life
prospective study on the consequences of weight loss after bariatric surgery on obese patients' spine.

Conditions: Low Back Pain in Obese Patients After Important Weight Loss

Summary: the purpose of this study is to determine how an important weight loss after bariatric surgery affects obese patients ' spine, and the effects it has on low back pain, sagittal alignment and lipomatosis .

obesity and back pain are massive public health problems, and the relationship between the two has not been described and studied. however, the investigators have also observed that many ex-obese patients still suffer from back and leg pain after an important weight loss. the aim of this study is to measure the effect of weight loss on back pain, and to find out what parameters can explain such modifications (increasing or decreasing back pain). the investigators will study clinical parameters, as well as radiological (to measure the effect of weight loss on spine sagittal alignment) and mri (to measure lipomatosis, which is a fat epidural accumulation, responsible for nerve compression and therefore back and leg pain).

Eligibility criteria:
inclusion criteria: * age \> 18 years old * bmi \> 40 or bmi \> 35 with comorbidities due to obesity ( criteria for bariatric surgery) * follow up in pompidou's hospital nutrition service * bariatric surgery intervention ( sleeve gastrectomy or by pass) * follow up possible for one year or more * being covered by french social insurance * consent to participate in the study exclusion criteria: * history of spine surgery * bariatric surgery postoperative complication * non mastering of french language * mri contraindication * patient under legal protection ( e.g. guardianship)

Keywords: bariatric spine obese low back pain sagittal alignment lipomatosis
functional epiphora management via different dacryocystorhinostomy (dcr) techniques

Conditions: Functional Epiphora (Tearing Without Any Anatomical Block)

Summary: 135 eyes of 135 patients treated between 2005 and 2017 will be included in this study. the diagnosis of functional epiphora was made based on a patent lacrimal system with a delay in the fluorescein dye disappearance test (fddt) or dacryoscintigraphy (dsg) without any ocular surface or eyelid abnormalities. the absence of epiphora and normalization of fddt postoperatively was defined as success. the study's hypothesis is that external dcr with a suitable technique will have better results compared to endonasal and transcanalicular dcr


Eligibility criteria:
inclusion criteria: * patent lacrimal irrigation and delay in the lacrimal transit time demonstrated by fluorescein dye disappearance test (fddt) or a dacryoscintigraphy (dsg) exclusion criteria: * dry eye (tear break up time less than 10 seconds), ocular surface disorders, eyelid malposition or laxity, orbicularis weakness, partial block or stenosis of the lacrimal drainage, history of previous nasal, lacrimal, or ophthalmic surgeries, and a postoperative follow-up time less than six months
evaluation of peripheral eos for the peripheral embolization treatment to rapidly occlude venous or arterial bleeding

Conditions: Hemorrhage; Bleeding

Summary: to collect confirmatory data in support of the safety and performance of the artventive medical group endoluminal occlusion system.

prospective, non-randomized, multi-center confirmatory observational study for the treatment of subjects with the need for vascular occlusion for the following conditions: 1. stopping blood loss from a damaged blood vessel from a traumatic vascular injury 2. hemorrhage caused by a neoplasia 3. neoplastic process (tumor) 4. gastrointestinal bleeding 5. closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous malformations or an arteriovenous fistula 6. interrupting blood supply to an organ or part of an organ for permanent devascularization 7. devascularization of tissues involved by a neoplastic process either pre-operatively or as a palliative measure 8. transjugular intrahepatic portosystemic shunt (tips)

Eligibility criteria:
inclusion criteria: 1. subjects aged ≥18 to ≤75 years. 2. subject with target vessels of 3.0 mm to 12 mm in diameter. 3. subject is able and willing to comply with all study requirements, including the required study follow-up visits. 4. subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the consent form. in the event of emergency procedure and subject and/or legal representative is unable to provide consent prior to study enrollment, consent will be obtained at earliest possible time following procedure for consent to continue to participate in the study. exclusion criteria: 1. subject has a known allergy to iodinated contrast for which they cannot be adequately premedicated. 2. subjects in whom venography or arteriography is contraindicated. 3. subjects with known hypersensitivity or contraindication to nickel or nitinol. 4. subject is pregnant or breastfeeding. 5. any clinical evidence that the investigator feels would place the subject at increased risk with the deployment of the device.

Keywords: embolization hemorrhage tips gi bleeding av fistula av malformation traumatic vascular injury
a non-interventional pilot study to explore the role of gut flora in migraine headaches

Conditions: Migraine

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to migraine headaches.

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. may be signed by parent or legal guardian in the case of minor or adult unable to provide consent 2. male or female of all ages. 3. diagnosis of migraine headaches by a physician exclusion criteria: 1. refusal to sign informed consent form 2. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. 3. postoperative stoma, ostomy, or ileoanal pouch 4. participation in any experimental drug protocol within the past 12 weeks 5. treatment with total parenteral nutrition
comparison of ionm between remimazolam and propofol

Conditions: Ossification Posterior Longitudinal Ligament; Cervical Spondylotic Myelopathy

Summary: inhalation anesthetics significantly can delay latency and reduce amplitude of cortical meps and sseps signals compared to intravenous anesthetics by acting on not only gaba (γ-aminobutyric acid) receptors but also nmda (n-methyl-d-aspartate) receptors, so total intravenous anesthesia (tiva) have been more preferred for neurophysiological monitoring follow-up during surgery. however, just less than inhalation anesthetics, the decrease of amplitude and the delay of latency also occur according to the dose dependant of propofol. moreover, it can cause various adverse effects such as delayed recovery after anesthesia or propofol infusion syndrome, consequently, combined methods with other agents or conversion to other relative anesthetics are being made. remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. recently, there have been repored that continuous infusion of 0.5-1.5 mg/kg of remimazolam has little effect on the motor evoked potential (meps) of cervical spine surgery patients, but this is a case report without the control group; further prospective studies are definitely needed. therefore, in the case of using propofol or remimazolam for total intravenous anesthesia, we aim to investigate which intravenous anesthetic is more appropriate for intraoperative neurophysiological monitoring by comparing the results of the somatosensory evoked potential (sseps) and meps according to these anesthetics.


Eligibility criteria:
inclusion criteria: * adult patients who aged 20-70 years with asa-ps 1-3, diagnosed of ossification of the posterior longitudinal ligament or cervical spondylotic myelopathy, in need of intraoperative neurophysiological monitoring exclusion criteria: * tolerance or hypersensitivity to benzodiazepine or propofol * dependence or addiction to psychotropic drugs or alcohol * previous brain-related neurosurgery * inserted status of pacemaker * inserted status of intracranial device * steroids use during surgery * pregnant women, subjects who lack the ability to make decisions and susceptible to voluntary participation decisions
multiple breath nitrogen washout in healthy and cystic fibrosis children

Conditions: Cystic Fibrosis; Healthy

Summary: this study compares the lung clearance index (lci) in cystic fibrosis and healthy children obtained with two different multiple breath nitrogen washout (mbwn2) devices. each participants will perform the test (lci) in duplicate on each device.

using nitrogen as the inert gas, there are currently two commercially available devices that offer the possibility to measure the lci. however, comparison between them are lacking. the 2 mbwn2 devices are the "easyone pro lab" (ndd medical technologies, zürich, switzerland) and the "exhalyzer d" (eco medics ag, duernten, switzerland).

Eligibility criteria:
inclusion criteria: * cystic fibrosis diagnosis exclusion criteria: * respiratory infection within 3 weeks * chronically infected with methicillin-resistant staphylococcus aureus or burkholderia cepacia

Keywords: lung clearance index cystic fibrosis multiple breath nitrogen washout
molecular pathways involved in cardiac remodeling in patients with chronic heart failure with preserved ejection fraction by new omics technologies

Conditions: Coronary Heart Disease

Summary: heart failure with preserved ejection fraction nowadays affects about half of all patients with heart failure. in the general population, the prevalence of this subclass of heart failure (hfpef, ed.) increases as the age of patients increases, especially in those over 65 years of age, and it has a significant gender. the study is to investigate the molecular pathways, predominantly protein patterns, involved in cardiac remodeling peculiar to heart failure with preserved ejection fraction (hfpef) by comparing them with remodeling pathways and protein pattern alterations in patients with hfref. in addition, the study aims to identify molecular alterations that would allow early identification of the development of ph-hfpef and ph-hfref, affecting the female gender more

the study, placing itself within the framework of translational research, aims to gain a greater understanding of the different phenotypes of patients with hfpef, to expand knowledge of the specific immune profile, and to identify new therapeutic targets for a heterogeneous clinical syndrome, to date lacking effective medical therapy. it is also proposed to find potential biomarkers with which to distinguish early between the two subclasses of decompensation and protein alterations related to the possible development of pulmonary hypertension in patients with hfpef and hfref (ph-hfpef and ph- hfref, respectively). patients who will take part in the study, following enrollment carried out on an inpatient or outpatient basis (being inpatients and control group subjects, respectively), will have follow-up visits at two times (at 1 month and at 6 months), in conjunction with regularly scheduled medical checkups, according to good clinical practice.

Eligibility criteria:
inclusion criteria: * heart failure patients exclusion criteria: * patients suffering from infectious diseases and serious infectious diseases

Keywords: molecular pathways cardiac remodeling coronary insufficiency